BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/23/2025 6:48:59 AM | Browse: 159 | Download: 452
Publication Name World Journal of Clinical Oncology
Manuscript ID 106646
Country Italy
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Antibody-drug conjugates in metastatic urothelial cancer: Highway to heaven
Manuscript Source Invited Manuscript
All Author List Alberto D’Angelo, Martina Catalano, Irene De Gennaro Aquino, Valeria Gangi and Giandomenico Roviello
ORCID
Author(s) ORCID Number
Giandomenico Roviello http://orcid.org/0000-0001-5504-8237
Funding Agency and Grant Number
Corresponding Author Giandomenico Roviello, Associate Professor, MD, PhD, Health Science, University of Florence, vialePieraccini, 6, florence 50139, Italy. giandomenico.roviello@unifi.it
Key Words Metastatic urothelial carcinoma; Antibody-drug conjugates; Enfortumab vedotin; Clinical efficacy
Core Tip Metastatic urothelial carcinoma (mUC) remains a challenging malignancy with poor prognosis despite advances in treatment. Platinum-based chemotherapy has been the standard, but its toxicity limits use in many patients. Immune checkpoint inhibitors have improved survival, yet most patients eventually progress. Antibody-drug conjugates (ADCs) represent a transformative approach, delivering cytotoxic agents directly to tumor cells while minimizing systemic toxicity. Enfortumab vedotin and sacituzumab govitecan have shown significant efficacy, even in heavily pretreated patients. Ongoing research aims to optimize ADC combinations and identify biomarkers for patient selection, paving the way for more personalized and effective mUC therapies.
Publish Date 2025-09-23 06:48
Citation

D’Angelo A, Catalano M, De Gennaro Aquino I, Gangi V, Roviello G. Antibody-drug conjugates in metastatic urothelial cancer: Highway to heaven. World J Clin Oncol 2025; 16(9): 106646

URL https://www.wjgnet.com/2218-4333/full/v16/i9/106646.htm
DOI https://dx.doi.org/10.5306/wjco.v16.i9.106646
Full Article (PDF) WJCO-16-106646-with-cover.pdf